西达本胺联合长春瑞滨软胶囊治疗HR阳性、HER-2阴性晚期乳腺癌的疗效及安全性

Efficacy and safety of citarbenamine combined with vinorelbine softgel in the treatment of HR-positive and HER-2 negative advanced breast cancer

目的研究联合应用西达本胺+长春瑞滨软胶囊治疗HR阳性、HER-2阴性晚期乳腺癌的疗效以及安全性。方法选取90例收治的HR阳性、HER-2阴性晚期乳腺癌患者,选取时间为2020年1月-2021年12月,采取抽签方式等分为两组,每组各45例。参照组单纯应用长春瑞滨软胶囊治疗,联合组则采取联合方案(西达本胺+长春瑞滨软胶囊)治疗。对比两组的治疗效果、肿瘤标志物指标水平、不良反应发生情况、无进展生存期以及1年生存率。结果联合组治疗有效率68.89%高于参照组治疗有效率(51.11%),组间有显著差异(P<0.05)。治疗后,两组肿瘤标志物(CA125、CA153、CEA、CYFRA21-1)水平均比治疗前水平低,且联合组指标水平低于参照组,数据差异有统计学意义(P<0.05)。联合组治疗后的白细胞减少、血红蛋白减少、血小板减少、肝功能异常、低钾血症、乏力以及胃肠道反应发生率均与参照组发生率无统计学意义(P>0.05)。联合组无进展生存期长于参照组,差异显著(P<0.05),且联合组1年生存率66.67%高于参照组(48.89%),组间差异有统计学意义(P<0.05)。结论HR阳性、HER-2阴性晚期乳腺癌患者的治疗中,应用联合治疗方案(西达本胺+长春瑞滨软胶囊)干预,可获得显著疗效,调节患者肿瘤标志物水平,且不会明显增加患者的不良反应,具有较高的安全性,有利于改善患者预后。

Objective To study the efficacy and safety of combined application of citabenamine plus vinorelbine softgel capsule in the treatment of HR-positive and HER-2 negative advanced breast cancer.Methods 90 patients with HR-positive and HER-2 negative advanced breast cancer were selected from January 2020 to December 2021 and divided into two groups by drawing lots,with 45 cases in each group.The reference group was treated with vinorelbine softgel alone,and the combination group was treated with the combination regimen(citabenamine+vinorelbine softgel).The therapeutic effect,tumor marker level,occurrence of adverse reactions,progressionfree survival and 1-year survival rate were compared between the two groups.Results The effective rate of treatment in combination group was 68.89%higher than that in reference group(51.11%),with significant difference between groups(P<0.05).After treatment,the levels of tumor markers(CA125,CA153,CEA,CYFRA21-1)in both groups were lower than before treatment,and the level of indicators in the combination group was lower than that in the reference group,with statistical significance(P<0.05).The incidence of leukopenia,hemoglobinia,thrombocytopenia,abnormal liver function,hypokalemia,fatigue and gastrointestinal reaction after treatment in combination group was not statistically significant compared with that in reference group(P>0.05).The progression-free survival time of the combination group was longer than that of the reference group,and the difference was significant(P<0.05).The 1-year survival rate of the combination group was 66.67%higher than that of the reference group(48.89%),and the difference between groups was statistically significant(P<0.05).Conclusion In the treatment of HR-positive and HER-2 negative advanced breast cancer patients,the intervention of combined treatment regimen(citarbenamine+vinorelbine soft capsule)can achieve significant efficacy,regulate the level of tumor markers in patients,and will not significantly increase the adverse reactions of patients,with high safety,and is beneficial to improve the prognosis of patients.